Cleared Traditional

K904022 - NITRO BLUE TETRAZOLIUM REDUCTION (FDA 510(k) Clearance)

Class I Pathology device.

K904022 · Sigma Chemical Co. · Pathology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Dec 1990
Decision
110d
Days
Class 1
Risk

K904022 is an FDA 510(k) clearance for the NITRO BLUE TETRAZOLIUM REDUCTION. Classified as Test, Leukocyte Alkaline Phosphatase (product code GHD), Class I - General Controls.

Submitted by Sigma Chemical Co. (St. Louis, US). The FDA issued a Cleared decision on December 18, 1990 after a review of 110 days - within the typical 510(k) review window.

This device falls under the Pathology FDA review panel, regulated under 21 CFR 864.7660 - the FDA pathology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Pathology review framework, consistent with the majority of Class II 510(k) submissions.

View all Sigma Chemical Co. devices

Submission Details

510(k) Number K904022 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received August 30, 1990
Decision Date December 18, 1990
Days to Decision 110 days
Submission Type Traditional
Review Panel Pathology (PA)
Summary -
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
33d slower than avg
Panel avg: 77d · This submission: 110d
Pathway characteristics
Predicate-based equivalence.

Device Classification

Product Code GHD Test, Leukocyte Alkaline Phosphatase
Device Class Class 1 - General Controls
CFR Regulation 21 CFR 864.7660
What this classification means

Class I devices are subject to general controls only and most are exempt from 510(k) premarket notification. They represent the lowest regulatory burden in the FDA device framework.